N
NuCana plc (NCNA)
NCM – Real vaqt narxi. Valyuta: USD
1.86
-0.11 (-5.58%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.90
+0.04 (2.15%)
Bozor oldidan: May 13, 2026, 5:27 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.86
-0.11 (-5.58%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.90
+0.04 (2.15%)
Bozor oldidan: May 13, 2026, 5:27 AM EDT
NuCana plc, klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda saraton bilan kasallangan bemorlarni davolash uchun dori vositalarini ishlab chiqish bilan shug'ullanadi. U buyurilgan kimyoterapiya vositalari va nukleozid analoglarini dori vositalariga aylantirish uchun o'zining ProTide texnologiyasini qo'llaydi. Kompaniya nukleozid analoglarining cheklovlarini bartaraf etish va saraton hujayralarida antikansor metabolitlarning konsentratsiyasini hosil qilish uchun dori vositalarini ishlab chiqmoqda. Uning quvuri tarkibiga metastatik kolorektal saraton bilan kasallangan bemorlarda 1b/2 fazali tadqiqotda bo'lgan, nukleozid analogi 5-ftorouratsildan olingan kimyoviy modda NUC-3373; ilg'or kolorektal saraton bilan kasallangan bemorlarni ikkinchi qator davolash uchun 2-faza klinik sinovi; va ilg'or qattiq o'smalar va o'pka saratoni bilan kasallangan bemorlar uchun 1b/2 fazali modulli klinik sinov kiradi. Shuningdek, u ilg'or qattiq o'smalar bilan kasallangan bemorlar uchun 1/2 fazali klinik sinovning 2-faza qismida bo'lgan 3'-dezoziadenozinning ProTide transformatsiyasi bo'lgan NUC-7738ni ishlab chiqmoqda. Purin va pirimidin asosidagi nukleozidlarni potentsial dori nomzodlari sifatida kashf qilish, dori dizayni va in vitro skrining qilish uchun Cardiff ProTides Ltd bilan topshiriq, litsenziya va hamkorlik shartnomasiga ega. Kompaniya ilgari NuCana BioMed Limited nomi bilan tanilgan va 2017 yil avgust oyida NuCana plc nomini olgan. NuCana plc 1997 yilda tashkil etilgan va Buyuk Britaniyaning Edimburg shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. | Chief Medical Officer |
| Dr. Stuart Grant | Senior Vice President of Regulatory Affairs |
| Mr. Gordon Kennovin | Senior VP of CMC & Development |
| Mr. Hugh Stephen Griffith | Founder, CEO & Executive Director |
| Mr. Ian Webster | Interim Chief Financial Officer |
| Mr. Martin Alexander Quinn | Company Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 6-K | d118567d6k.htm |
| 2026-03-19 | S-8 | d19997ds8.htm |
| 2026-03-19 | 20-F | ncna-20251231.htm |
| 2026-01-06 | 6-K | d19790d6k.htm |
| 2025-12-17 | 6-K | d46511d6k.htm |
| 2025-12-10 | 6-K | d23141d6k.htm |
| 2025-11-13 | 6-K | d936510d6k.htm |
| 2025-11-05 | 6-K | d87120d6k.htm |
| 2025-10-20 | 6-K | d917681d6k.htm |
| 2025-10-14 | 6-K | d88344d6k.htm |
| Ms. Theresa Bruce | Chief Operating Officer |
| Prof. David Harrison | Head of Translational Medicine & Studies |